The CCR5 delta-32 heterozygote subject is enrolled in Sangamo's clinical trial and, as part of the clinical trial protocol, is undergoing an ART treatment interruption , which is ongoing.
http://www.biospace.com/news_story.aspx?StoryID=313191&full=1
http://www.biospace.com/news_story.aspx?StoryID=313191&full=1
No comments:
Post a Comment